Production Of A Novel Humanised Anti Dendritic Cell Therapeutic Antibody For Graft Versus Host Disease
Funder
National Health and Medical Research Council
Funding Amount
$202,500.00
Summary
A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be use ....A transplant of bone marrow or other source of blood stem cells from a donor is often used to treat leukaemia patients whose disease has failed to respond to chemotherapy. The Mater Medical Research Institute has developed a world first dendritic cell depleting therapeutic antibody which may open a new strategy for the control of acute graft versus host disease, which is a very common and often fatal complication of bone marrow transplantation. The new antibody treatment is also likely to be useful for the prevention of rejection in solid organ transplantation. If successful, it will selectively control graft versus host disease, without compromising the essential anti-viral immunity and desired anti-leukemia activity of the graft.Read moreRead less
Novel Targeted PEG Nanoparticles For Cancer Treatment And Monitoring
Funder
National Health and Medical Research Council
Funding Amount
$606,979.00
Summary
We will develop novel targeted cancer therapies based on next generation nanoparticles. These particles will deliver highly potent drugs to tumours with less adverse effects to healthy organs. The ability to image the therapeutic can be used to detect diseases at early, potentially curable stages, identify patients likely to respond to certain treatments, and predict response to therapy. Our project has the potential to increase the survival of patients suffering from the most deadly cancer.
Next Generation Imaging To Bridge The Knowledge Gap In Nanomedicine Delivery
Funder
National Health and Medical Research Council
Funding Amount
$483,402.00
Summary
Nanomedicines are generally touted as the next generation in therapeutics. However, despite some landmark successes, their translation into clinical use is limited. This is mainly a result of poor understanding of how they behave under physiological conditions. To address this issue and improve translation, this fellowship aims to develop predictive models of how nanomedicines interact with biological systems, then validate the nanomedicines in dog models of cancer that mimic the human disease.
Immuno-polymeric Drugs For Prostate Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$626,995.00
Summary
Prostate cancer is the most common cancer in men over 50 and the second most frequent cause of cancer deaths in Western society. Docetaxel is the first line of chemotherapy when other intervention strategies are unsuccessful, but 30% of patients suffer from severe side-effects. To address this problem, we will utilise carriers for docetaxel that directly target prostate tumours using a novel antibody approach. This increases accumulation at the tumour site while decreasing off-target toxicity.
Monoclonal antibodies, such as the cancer therapeutic Pembrolizumab, have revolutionised the treatment of cancer and many inflammatory conditions. With over $100 billion in sales in 2018, they also underpin a growing biotech industry. We have developed a highly specific, high affinity therapeutic antibody candidate, and demonstrated efficacy in animal models of malignancy. This project will advance and develop this monoclonal, allowing us to initiate clinical studies in patients.
Stability Engineering Of Human Antibody Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$421,104.00
Summary
Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pha ....Therapeutic monoclonal antibodies are among the fastest growing class of drugs with more than $30 billion sales in 2011. Unfortunately, antibodies often display limited stability and a tendency to aggregate. This greatly hinders their development and results in high failure rates of otherwise promising candidates. We have recently identified mutations that render human antibodies resistant to aggregation. Here we apply this technology to a monoclonal antibody candidate developed by a leading pharmaceutical company.Read moreRead less
IMMUNOTARGETED NANOPARTICLES TO IMPROVE TUMOUR DELIVERY OF CHEMOSENSITISING CYTOTOXIC DRUGS AND B-RADIATION
Funder
National Health and Medical Research Council
Funding Amount
$548,985.00
Summary
This project aims to develop nano-bullets for advanced cancer therapy and nano-probes for the early assessment of cancer treatment responses, improved patient outcomes and reducing drug development time. Specially engineered, antibody-coated nanoparticles are targeted to dead cancer cells, present in untreated cancer but increased after therapy, for (1) tumour site specific delivery of increased drug or radiation dose than currently achieved and (2) monitoring the tumour response to therapy.
SIGN Receptors And The Antiinflammatory Activity Of Sialylated IgG Fcs
Funder
National Health and Medical Research Council
Summary
IgG antibodies are a crucial component of the immune system, and significantly contribute to host protection against cancer and infectious diseases. Additionally, therapeutic IgG antibodies have been developed for treatment of cancer and inflammatory diseases. The studies proposed herein will elucidate one important aspect of how IgG antibodies act as anti-inflammatory agents, and may lead to the design of more effective IgG based therapies for the treatment of inflammatory diseases or cancer.
Relaxin Receptor Structural Determination To Aid Therapeutic Development
Funder
National Health and Medical Research Council
Funding Amount
$1,249,114.00
Summary
The receptor for the peptide hormone relaxin, RXFP1, is being targeted by numerous drug companies for the treatment of cardiovascular disease. However, the lack of molecular detail of how relaxin binds and activates RXFP1 is hindering new drug development. We will determine the structure of the complex of relaxin bound to RXFP1 and the mechanism by which this activates cells. The knowledge gained will aid in the design of new drugs targeting RXFP1 for the treatment of cardiovascular disease.